Drug-induced arrhythmias remain a major challenge in drug development and can lead to severe cardiovascular complications or withdrawal of approved drugs from the market. This research highlights the application of CiPA-qualified human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as a reliable and human-relevant model for evaluating cardiac safety.

In this study, YBLiCardio cardiomyocytes developed by Yashraj Biotechnology Ltd. were used to assess the effects of 28 pharmaceutical compounds using advanced electrophysiological measurements. The results demonstrated strong correlation with established CiPA reference data and showed improved predictive accuracy for identifying proarrhythmic risk.

These findings emphasize the potential of hiPSC-derived cardiomyocytes as a robust platform for cardiotoxicity assessment, supporting safer and more efficient preclinical drug discovery and development.